TriangleNCT00102739 · CITED IN SOURCE DOCUMENTS
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2013-04-15
This study is a double-blind, randomized, placebo-controlled, parallel group, repeat-dose, study conducted in two parts (Part A and Part B) examining 30, 50, and 75 mg doses of SB-497115-GR as a treatment for patients with ITP who have failed prior therapy. The study is designed to determine the proportion of patients with a platelet count =50,000/µL after 42 days. In Part B, 99 newly-recruited subjects will be randomized to one of two dosing arms in a 2:1 ratio of active:placebo. During the 6 week study period, subjects will start on placebo or active drug (50 mg) and may have a dose increase to 75 mg based upon their platelet count at day 22.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- Inclusion criteria: * Patients with chronic low platelet count (less than 30,000/µL) for 6 months who have failed at least one treatment for chronic low platelet count. * Patients receiving chronic maintenance steroid therapy must have received a stable dose for at least 1 month. * Normal PT and PTT. Exclusion criteria: * History of clotting disorder. * Females who are pregnant or are receiving hormone replacement therapy or systemic contraceptives. * History of alcohol/drug abuse or dependence within 1 year. * Use of aspirin, aspirin-containing compounds, salicylates, antacids, rosuvastatin, pravastatin, non-steroidal anti-inflammatory drugs during the study and within 3 weeks prior to starting the study. * History of HIV infection or active infection with Hepatitis B or C.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- interventions
- name
- SB497115
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- DOUBLE
- who Masked
- PARTICIPANT
- INVESTIGATOR
- primary Purpose
- TREATMENT
Enrollment
- count
- 99
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- measure
- Treatment response, assessed by the proportion of patients with platelet counts of =50, 000/µL (compared with baseline count of <30, 000/µL) after 42 days of treatment.
- secondary Outcomes
- measure
- Safety, tolerability, PK, PD, symptoms associated with ITP, and QoL, odds of response vs placebo during weeks 2 to 6 of the study.
Full study description
- brief Summary
- This study is a double-blind, randomized, placebo-controlled, parallel group, repeat-dose, study conducted in two parts (Part A and Part B) examining 30, 50, and 75 mg doses of SB-497115-GR as a treatment for patients with ITP who have failed prior therapy. The study is designed to determine the proportion of patients with a platelet count =50,000/µL after 42 days. In Part B, 99 newly-recruited subjects will be randomized to one of two dosing arms in a 2:1 ratio of active:placebo. During the 6 week study period, subjects will start on placebo or active drug (50 mg) and may have a dose increase to 75 mg based upon their platelet count at day 22.
- detailed Description
- A double-blind, randomized, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of SB-497119-GR, a thrombopoietin receptor agonist, administered at 30, 50, and 75 mg as oral tablets once-daily for 6 weeks to adult male and female subjects with refractory, chronic immune thrombocytopenia purpura
Source references
- references
- citation
- Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007 Nov 29;357(22):2237-47. doi: 10.1056/NEJMoa073275.
- pmid
- 18046028
- type
- BACKGROUND
- citation
- Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2011 Jun;51(6):842-56. doi: 10.1177/0091270010375427. Epub 2010 Jul 27.
- pmid
- 20663993
- type
- BACKGROUND
- citation
- Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis. 2013 Apr;24(3):284-96. doi: 10.1097/MBC.0b013e32835fac99.
- pmid
- 23492914
- type
- DERIVED
- citation
- Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Feb 21;373(9664):641-8. doi: 10.1016/S0140-6736(09)60402-5.
- pmid
- 19231632
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-202ca8677a01a502edea
- requested nct id
- NCT00102739
- primary nct id
- NCT00102739
- source kind
- fda_spl_label
- source record id
- b8a1cc48-9aaf-486a-9305-090acccb5c02
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- 8c52ba498b7145ab92be11fd5a38a4cdf0b3ad1d30b565ac4868e64f285765eb
- payload
- application numbers
- NDA022291
- NDA207027
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-202ca8677a01a502edea
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00102739
- occurrences
- context exact
- acebo-controlled trials and in an open-label extension trial. In Study TRA100773B and Study TRA100773A (referred to as Study 773B and Study 773A, respectively [NCT00102739]), patients who had completed at least one prior ITP therapy and who had a platelet count less than 30 x 10 9 /L were randomized to receive either PROMACTA or
- end
- 367
- exact text
- NCT00102739
- start
- 356
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/22/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- b8a1cc48-9aaf-486a-9305-090acccb5c02
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- a20476f81499eaadcb663d2457610e22126a4bc539ff02f3708748bd8a52b5b2
- spl effective time
- 20251218
- spl set id
- 7714a0ed-34bb-46e6-a0a5-b363908b22c2
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-777da1426a7d30fe3b5b
- requested nct id
- NCT00102739
- primary nct id
- NCT00102739
- source kind
- fda_spl_label
- source record id
- 6a49af27-c1fc-4b62-8c30-fb27bc4c5a3e
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- payload sha256
- 9eab8c3dc4745c10b41c09c224bb705d43d9e6b846535501da94de28b3aed5fc
- payload
- application numbers
- NDA216774
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-777da1426a7d30fe3b5b
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00102739
- occurrences
- context exact
- acebo-controlled trials and in an open-label extension trial. In Study TRA100773B and Study TRA100773A (referred to as Study 773B and Study 773A, respectively [NCT00102739]), patients who had completed at least one prior ITP therapy and who had a platelet count less than 30 x 10 9 /L were randomized to receive either eltrombopag
- end
- 816
- exact text
- NCT00102739
- start
- 805
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00400.json
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source json pointer
- /results/26/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 6a49af27-c1fc-4b62-8c30-fb27bc4c5a3e
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 2489e59675590c985cc57ea1c1dd6faf4d44f2d73e6e584bcf6e19c70532f8a2
- spl effective time
- 20260101
- spl set id
- ed51e463-7a03-4858-bbd2-882ce4753d5a
Preserved source evidence · Not medical advice